VU0405601 is a potent KV11.1 channel activator. VU0405601 protects cardiac tissue from dofetilide -induced ventricular tachycardia.
VU0405601 (5 µM; pretreated for 30 min before 100 nm dofetilide) protects cardiac tissue from dofetilide -induced ventricular tachycardia[2].
VU0405601 (50 µM) can be used as a hERG agonist and increases test pulse and tail currents, increases the IC50 of dofetilide from 38.7 to 76.3 nm[2].
References:
[1]. Egly CL, et al. A High-Throughput Screening Assay to Identify Drugs that Can Treat Long QT Syndrome Caused by Trafficking-Deficient KV11.1 (hERG) Variants. Mol Pharmacol. 2022 Apr;101(4):236-245.
[2]. Potet F, et al. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias. J Biol Chem. 2012 Nov 16;287(47):39613-25.